SCHEMBL4604283

SCHEMBL4604283

COC(=O)c1ccc2ccn(-c3ccccc3)c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.56
KDM4E B2RXH2 3/20 0.50
HPGD P15428 3/20 0.50
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
POLB P06746 1/20 0.50
APOBEC3A P31941 1/20 0.50
HSD17B10 Q99714 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
NPC1 O15118 1/20 0.46
TSHR P16473 1/20 0.46
NR4A2 P43354 1/20 0.46
CYP3A4 P08684 2/20 0.46
LMNA P02545 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
TRPA1 O75762 1/20 0.43
MEN1 O00255 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30201534 1.00 FGFR1 (0.56) FGFR1KDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL3975054 0.89 FGFR1 (0.60) FGFR1KDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL25998835 0.87 CA12 (0.51) FGFR1KDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL346432 0.87 TDP1 (0.51) FGFR1KDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL18002655 0.86 KDM4E (0.54) KDM4EHPGDALDH1A1SMN1; SMN2POLB
SCHEMBL16720753 0.86 ALDH1A1 (0.48) FGFR1KDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL18002810 0.85 POLB (0.46) FGFR1KDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL3491657 0.84 ALDH1A1 (0.46) FGFR1KDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL24950460 0.83 FGFR1 (0.55) FGFR1KDM4EHSD17B10TSHRF2
SCHEMBL30201454 0.83 FGFR1 (0.55) FGFR1KDM4EHSD17B10TSHRF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4376818-B1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC (US) 2025-06-18 EP disclosed
US-12209084-B2 Serotonin 5-HT2B inhibitory compounds ZOETIS SERVICES LLC (US) 2025-01-28 US disclosed
CN-117729914-A Serotonin 5-HT2B inhibiting compounds 硕腾服务有限责任公司 2024-03-19 CN disclosed
US-20230071039-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC 2023-03-09 US disclosed
CN-102124012-B Macrocyclic indole derivatives useful as hepatitis C virus inhibitors TIBOTEC PHARM LTD 2014-07-02 CN disclosed
CN-102124012-A Macrocyclic indole derivatives useful as hepatitis C virus inhibitors TIBOTEC PHARM LTD 2011-07-13 CN disclosed
EP-1937674-A1 ISOXAZOLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-07-02 EP disclosed
US-7378435-B2 Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-27 US disclosed
WO-2007042420-A1 ISOXAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-19 WO disclosed
US-20070082936-A1 Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives HOFFMANN-LA ROCHE INC. 2007-04-12 US disclosed
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MARZABADI MOHAMMAD R 2007-02-22 US disclosed
US-7067534-B1 Substituted anilinic piperidines as MCH selective antagonists H. LUNDBECK A/S (DK) 2006-06-27 US disclosed
EP-1411942-A4 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS SYNAPTIC PHARMA CORP (US) 2005-01-26 EP disclosed
EP-1411942-A1 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS Synaptic Pharmaceutical Corporation (US) 2004-04-28 EP disclosed
US-6727264-B1 MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS SYNAPTIC PHARMACEUTICAL CORPORATION 2004-04-27 US disclosed
WO-2003004027-A1 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230071039-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS HTR2B, HTR1B, HTR1A FGFR1 2146/4885KDM4E 2243/4885HPGD 1179/4885
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MCHR1, MCHR2, MC1R FGFR1 1344/4885KDM4E 1353/4885HPGD 2602/4885
US-12209084-B2 Serotonin 5-HT2B inhibitory compounds HTR2B, HTR1B, HTR1A FGFR1 2146/4885KDM4E 2243/4885HPGD 1179/4885
US-20070082936-A1 Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives GABRA5, GABRA4, CHRNA5 FGFR1 1071/4885KDM4E 964/4885HPGD 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.